Biogen & Eisai
9 shared events · Importance 3 · Last updated May 25, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
Biogen: Biogen produces lecanemab (Leqembi), an anti-amyloid drug whose efficacy was challenged by the Cochrane review, which could negatively affect its market performance.
Eisai: Eisai co-produces lecanemab (Leqembi), an anti-amyloid drug whose effectiveness was disputed by the Cochrane review, potentially leading to financial repercussions.
Apr 16, 2026 · 6 articles
Business
Biogen: Biogen is a partner in Leqembi commercialization; the sales results contribute to its Q2 2026 report.
Eisai: Eisai reported Leqembi sales of JPY 29.3 billion in Q2 2026, driving its revenue and partnership with Biogen.
Jul 29, 2026 · 6 articles
Business
Biogen: Biogen collaborates with Eisai on Leqembi development and commercialization, benefiting from the India launch through co-commercialization.
Eisai: Eisai is the primary actor, launching Leqembi in India, which could drive revenue growth and strengthen its position in the Alzheimer's treatment market.
Aug 03, 2026 · 6 articles
Business
Biogen: Joint development and commercialization partner for lecanemab; benefits from increased sales.
Eisai: Partner responsible for development and commercialization; launched Leqembi Iqlik in the US, expanding its Alzheimer's franchise.
Aug 24, 2026 · 6 articles
Business
Biogen: Biogen is a joint development and commercialization partner for Lecanemab, participating in clinical studies. While not the primary focus of this sales forecast, it benefits from the drug's success.
Eisai: Eisai, as the primary developer and commercializer of Lecanemab, presented the sales simulation, indicating strong future revenue growth for the company. This positively impacts its financial projections and market position.
May 25, 2026 · 7 articles
Tech
Biogen: Greta Duréel has consulted for Biogen, but no direct impact from this study.
Eisai: Greta Duréel has consulted for Eisai, but no direct impact from this study.
Aug 12, 2026 · 6 articles
Business
Biogen: Biogen, in collaboration with Eisai, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Eisai: Eisai, in collaboration with Biogen, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
Business
Biogen: Biogen entered into a joint development and commercialization agreement for lecanemab with Eisai in 2014 and is involved in the AHEAD 3-45 clinical study.
May 15, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Biogen and Eisai interact across events, view sentiment trends, and discover connected entities.
Open Dashboard